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Poster Session II S309than 1000/microlitter following conditioning. Considering platelets,
157 and 12 of patients did not have platelet count less than 20,000
and 100,000/mcrolitter after transplantation respectively. There
was no difference for engraftement days between ABO mismatched
and matched group. The median RBC transfusion requirement
was 7 units prior to 100 days post-HCT and 8 units through one
year post-HCT and overall follow-up across all recipients.
Table 1. RBC transfusions in ABO major/bidirectional mis-
matched and matched donor-recipient pairs.
Major/bidirectional
All patients missmatch Match P-Valueat 100 days 7.5 8 6 0.11
at 1 year 8 10 8 0.071
overall 8 11 8 0.043A significantly higher total number of RBC transfusions occurred in
major and bidirectional ABO mismatches compared to ABO
matched transplants (11 units vs 8 units; p5 0.043); however, trans-
fusional requirements were only modestly increased throughout the
first year following transplantation in major/bidirectional mismatch
group (10 units vs. 8 units; p 5 0.061). The increase in overall RBC
transfusion was not associated with differences in rates of GVHD,
disease relapse, or overall survival.
Conclusion:ABOmismatchmay be associated with an increased re-
quirement for RBC transfusion after TLI/ATG conditioining.Man-
agement strategies for excessive RBC transfusion after ABO major
mismatched HCT require further study but may target persistent
recipient plasma cells secreting anti donor ABO antibodies.427
OUTCOME OF SECOND ALLOGENEIC STEM CELL TRANSPLANTATION
(SCT) IN PEDIATRIC PATIENTS WITH GRAFT FAILURE OR RECURRENT
LEUKEMIA
Pawlowska, A.B.1, Cheng, J.2, Stiller, T.3, Palmer, J.3, Hafeez, N.1,
Rosenthal, J.1 1City of Hope National Medical Center, Duarte, CA;
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Both graft failure or leukemia relapse after an allogeneic SCT are
associated with high mortality rate and available treatment options
are limited. We report 22 patients (age 3.9-19.7 years) with hemato-
logical malignancies who received second allogeneic SCT at COH
from 4/2000 – 12/2009 for graft failure (8 patients: AML–3 patients,
ALL-3 patients, CML-1 patient, Lymphoma-1 patient) or recurrent
leukemia (ALL-5 patients, AML-9 patients). Reduced intensity reg-
imen was used in 18 patients; only 4 received myeloablative condi-
tioning. 9 (41%) patients received transplants from the same
donor, and in13 (59%) a different donor was used. Half of the pa-
tients (11) received the second SCT within a year of the first SCT
(median: 391 days, range: 44-1,715). Overall survival for the whole
group at 100 days and 2 years were 77% (60-88%), 45% (35-
55%), respectively. The median follow-up for the 8 (36%) surviving
patients was 4.5 years (range: 0.5-10.6). Patients with graft failure
had superior overall survival (75% at 2 years) compared with recur-
rent disease (28%, p5 0.04) Less advanced disease status (1CR/2CR
vs 3CR/active disease) and diagnosis of non-ALL were associated
with higher likelihood of survival (p 5 0.02, p 5 0.02, respectively).
Survival for patients with less than one year between transplants
(31% at 2 years) did not differ from those receiving the second
SCT later than one year (60%, p 5 0.81). Within 100 days post
transplant 3 patients were diagnosed with CMV, 3 patients with
other viral infection (adeno, VZV, HSV), 12 patients had 23 culture
proven episodes of bacterial infections, 5 patients developed Clos-
tridium difficile enterocolitis and 1 patient was diagnosed with As-
pergillus fumigatus. In summary, second SCT used for graft
failure or leukemia relapse in pediatric patients with hematological
malignancies is associated with acceptable transplant related toxicity
and infection rates. For patients with graft failure the long term out-
come is excellent; for patients with relapsed leukemia second trans-
plant should be offered as a treatment option as it can lead to long
term disease free survival.428
ELEVATED PRE TRANSPLANT SERUM FERRITIN IS ASSOCIATEDWITH IN-
CREASED RISK OF INVASIVE MOLD INFECTION (IMI) AFTER ALLOGENEIC
HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT)
Dadwal, S.2, Tegtmeier, B.2, James, I.2, Forman, S.1, Pullarkat, V.1
1City of HopeMedical Center, Duarte, CA; 2City of HopeMedical Center,
Duarte, CA
Elevated pre transplant serum ferritin, a measure of iron overload
is associated with various adverse outcomes after allogeneic HSCT
including increased risk of fungal infections. Invasivemold infections
(IMI) are life threatening complications after allogeneic HSCT and
are mostly caused byAspergillus species and Zygomycetes. Small case
series have shown elevated iron stores in HSCT patients who devel-
oped IMI. We examined if elevated serum ferritin prior to HSCT
was associated with increased risk of IMI after allogeneicHSCT. Pa-
tients who underwent allogeneic HSCT from March 2005 through
December 2009, in whom a pretransplant ferritin level was available,
are included in this analysis. Serum ferritin was measured upon ad-
mission for HSCT prior to initiation of conditioning regimen.
Proven or probable IMI was diagnosed according to EORTCMyco-
sis Study Group criteria. Elevated serum ferritin was defined as
values above 1000 ng/ml. Pretransplant ferritin levels were available
in 478 patients. 9 patients (1.9%) had developed IMI at day 30 and 21
patients (4.4%) had IMI at day 100. Among the high ferritin group, 8
of 220 patients developed an IMI within 30 days after HSCT com-
pared to 1 of 258 patients in the low ferritin group (P 5 0.01). 14
of 220 and 7 of 258 patients in the high and low ferritin groups re-
spectively had developed an IMI by day 100 after HSCT (P 5
0.043). The median ferritin level in patents who had IMI at day 30
was 1810 ng/ml compared to 940 ng/ml in those who did not develop
IMI (P 5 0.006). For patients who developed IMI within 100 days
after HSCT, the median ferritin level was 1420 compared to 940
ng/ml for those who were free of IMI. Iron overload as measured
by pretransplant serum ferritin is associated with increased risk of
IMI after allogeneic HSCT. Fungal prophylactic strategies that
cover IMI are particularly important in iron overloaded recipients
of allogeneic HSCT.429
IN VIVO T-CELL DEPLETION (TCD) DOES NOT IMPROVE RATES OF
GRAFT-VERSUS-HOST DISEASE (GVHD) AND TRANSPLANTATION OUT-
COMES IN PATIENTS UNDERGOING PERIPHERAL BLOOD ALLOGENEIC
HEMATOPOIETIC CELL TRANSPLANT (AHCT)
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In vivoTCD is commonly employed to prevent graft rejection and
GVHD in patients undergoing AHCT. Published (but controver-
sial) data suggest possible benefit with TCD in the setting of unre-
lated donor (URD), and HLA-mismatched AHCT. We report
here outcomes for patients who received TCD with transplant
conditioning (TCD group) and compare them with patients who
received T-cell replete allografts (non-TCD group).
The study cohort consists of 150 consecutive patients who under-
went AHCT between 2003 and 2009. All patients received periph-
eral blood allografts. TCD consisted of alemtuzumab (20mg on
days -4 and -1; n5 39) or thymoglobulin 6 mg/kg (total dose) for ab-
lative and reduced intensity conditioning transplants and 7.5 mg/kg
(total dose) for non myeloablative allografts (n 5 51). 4 patients
received Atgam at 30mg/kg on days -5 to -3.
Patient characteristics of TCD and non-TCD groups are shown
in table 1. Significantly more patients in the TCD group had high
risk disease (86.3% v 61.8%, p\ 0.05) and received AHCT from
URD (62.1% v 29.1%, p\0.05). Median follow-up of surviving pa-
tients is 3yrs. There was no significant difference between engraft-
ment kinetics of two groups. The rates of acute GVHD II-IV in
the TCD and non-TCD groups were 42.1% (n 5 40) and 50.9%
(n 5 28) respectively (p0.32).On subgroup analysis rates of acute
GVHD II-IV in the TCD and non-TCDgroups for matched sibling







Men 60 (63) 34 (62)
Women 35 (37) 21 (38)
Age: median (range) 50 (17-69) 48 (20-63)
Diagnosis: n (%)
Acute Leukemia/MDS 53 (56) 35 (64)
Non-Hodgkin Lymphoma 23 (24) 4 (7)
Chronic Leukemia 9 (9) 14 (25)
Others 10(11) 2 (4)
Conditioning regimen: n (%)
Myeloablative 69 (72.6) 45 (81.8)
Reduced intensity / non-myeloablative 26 (27.4) 10 (18.2)
Risk group: n (%)
Standard risk 13 (14) 21 (38)
High risk 82 (86) 34 (62)
Donor type: n (%)
Sibling 36 (37.9) 39 (70.9)
Unrelated 59 (62.1) 16 (29.1)
HLA mismatch: n (%) 13 (13.7%) 4 (7.3%)
CD 34+ dose: median (range) x
10*6/Kg body wt.
6.2 (1.9-16) 5.4 (1.2-12.9)
S310 Poster Session II(28.9% v 50%; p5 0.06), URD (48.3% v 64.7%; p5 0.23) andHLA
mismatched AHCT (p5 0.59), were not significantly different. The
incidence of chronic GVHD in the TCD and non-TCD groups was
41.1% (n 5 39) and 45.5% (n 5 25) respectively (p0.86). On sub-
group analysis of patients undergoing matched sibling, URD and
HLA-mismatched AHCT, no significant difference in rates of
cGVHD between the two groups was seen (p . 0.05). Relapse rates
in the TCD and non-TCD groups were 32.6% and 40% (p 5 0.22)
respectively. The overall survival at 3years was 39.2% in the TCD
group and 39.3% in the non-TCD group; p5 0.93. The 3year pro-
gression free survival in similar order were 34.8% and 27.2% respec-
tively (p5 0.85). Non relapse mortality at day 100 respectively were
12.8% and 16% and at 3years were 40% and 41% (p . 0.05).
Our limited, single institution experience in a cohort of 150 con-
secutive patients suggest no significant benefit with routine use of in
vivo TCD with AHCT. These results highlight the need to develop
novel strategies for preventing GVHD and for improving transplan-
tation outcomes.430
OUTCOMES FOLLOWING HEMATOPOIETIC CELL TRANSPLANTATION
FOR WISKOTT ALDRICH SYNDROME
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Human leukocyte antigen (HLA) identical sibling donor trans-
plantation remains the treatment of choice forWiskott Aldrich Syn-
drome (WAS), however, utilization of alternative donor sources has
significantly increased since 1990. We report the hematopoietic cell
transplantation (HCT) outcomes of 47 patients withWAS treated at
a single center since 1990 with significant improvement in outcomes
after 2000 despite the increased use of alternative donors. 5 year
overall survival (OS) improved from 62.5% (95% CI: 34.9% to
81.1%) to 90.8% (95% CI: 67.7% to 97.6%) for patients trans-
planted during 1990-2000 and 2001-2009, respectively. When
adjusted for age at HCT, OS was significantly higher in the 2001-
2009 era (p 5 0.04, Cox proportional hazard analysis). No early
transplant related mortality (within the first 100 days) occurred
among patients transplanted during 2001-2009 compared to 3/16
during 1990-2000, (p 5 0.03, Fisher’s exact test). The extent of
HLA mismatch did not significantly affect the incidence of acuteGVHD, chronic GVHD, or survival. Post-HCT autoimmune cyto-
penias were frequently diagnosed after 2001: 17/31 (55%) patients.
Their occurrence was not associated with transplant donor type
(p 5 0.53), or occurrence of acute GVHD (p 5 0.74), chronic
GVHD (p 5 0.12), or mixed chimerism (p 5 0.50).431
ALLOGENEIC STEM CELL TRANSPLANTATION FOR CHRONIC ACTIVE EBV
INFECTION (CAEBV)
Craddock, J.A.1, Bollard, C.M.1, Krance, R.A.1, Cowan, M.J.2,
Cairo, M.S.3, Heslop, H.E.1, Gottschalk, S.1 1Baylor College of Medicine,
Houston, TX; 2UCSF Children’s Hospital, San Francisco, CA; 3Columbia
University, New York, NY
Chronic active Epstein Barr virus infection (CAEBV) encom-
passes a variety of EBV-associated lymphoproliferative diseases
(LPD) in the non-immunocompromised host. In CAEBV either B,
T, and/or NK cells are primarily infected with EBV and patients
present with a variety of clinical signs and symptoms including fever,
hepatosplenomegaly, and lymphadenopathy. While rare in the
Western hemisphere, T and NK cell CAEBV is most commonly
seen in Japan. In Japan, current treatment protocols rely on chemo-
therapy and hematopoietic stem cell transplantation (HSCT).
To evaluate the clinical outcome of HSCT in CAEBV patients in
the United States, we reviewed our experience with 6 CAEBV pa-
tients (4 T-cell, 1 NK-cell, 1 B-cell), who underwent allogeneic
HSCT for their disease. Median age at transplant was 11 yrs (range
6 – 25 yrs) and the median time to transplant from diagnosis was 3.7
years (range 4.3 yrs – 8.5 yrs). Four of 6 patients had persistent or re-
fractory disease at the time ofHSCT. Four patients receivedmyeloa-
blative conditioning while 2 patients received reduced intensity
conditioning (RIC). Median time to neutrophil engraftment was
16 days (range days 11 – 21 days) with no long-term engraftment fail-
ure. Five patients received infusions of donor derived EBV-specific
cytotoxic T cells (CTLs) at a median of 6 months (range 2.5 months
– 12 months) post HSCT. Five patients are alive and in complete re-
mission with a median survival of 2.5 yrs (range 7 months – 10 yrs).
One patient developed recurrent T-cell CAEBV immediately post
transplant and died of an aggressive T-cell lymphoma 3.7 years
post transplant.
Our results support published data from Japan showing good out-
comes for CAEBV patients after allogeneic HSCT. Factors that may
influence outcome and warrant further study include the timing of
transplantation after diagnosis and the use of EBV-directed T-cell
therapies.432
HAPLOIDENTICAL STEM CELL TRANSPLANTS IN CHILDRENWITH ACUTE
LYMPHOBLASTIC LEUKEMIA IN FIRST OR SECOND REMISSION
Kennedy-Nasser, A.A., Leung, K.S., Martinez, C.A., Bollard, C.M.,
Gottschalk, S., Craddock, J.A., Ahmed, N., Heslop, H.E.,
Brenner,M.K., Krance, R.A. Baylor College ofMedicine, Texas Children’s
Hospital, Houston, TX
Allogeneic hematopoietic stem cell transplant (SCT) offers cura-
tive therapy to children with high-risk or relapsed acute lymphoblas-
tic leukemia (ALL). Here, we report encouraging results using
haploidentical related donor CD34+ selected (T-cell depleted) pe-
ripheral blood stem cell transplants in children with ALL in first
or second remission (CR1 or CR2). From May 2002 to September
2009, we transplanted 17 children (13 male, 4 female) in CR1 (n 5
6) and CR2 (n5 11) using primarily a fully myeloablative condition-
ing regimen consisting of cyclophosphamide 45mg/kg x 2 doses, cy-
tarabine arabinoside 3gm/m2 x 6 doses and total body irradiation
(TBI) 1400cGy (n5 12). Five patients received either a reduced-in-
tensity regimen or busulfan-based regimen for clinical purposes
(such as to avoid TBI exposure). All patients received alemtuzumab
(3, 5 or 10mg/dose depending on body weight) during conditioning
for in vivo T-cell depletion to promote engraftment and provide ad-
ditional GvHD protection. If the infused T-cell dose was less than
